Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study

Wagner F. GattazDepartment and Institute of Psychiatry, and Laboratory of Neuroscience (LIM27), University of São Paulo Medical SchoolBrazilCorrespondence[email protected]

João Alberto de Oliveira CamposDepartment of Psychiatry, Federal University of Goiás GoiâniaBrazil

Acioly L.T. LacerdaDepartment of Psychiatry, Federal University of São PauloBrazil

Elaine HennaInstitute of Psychiatry Prof. André Teixeira Lima Sorocaba, São PauloBrazil

Sandra Inês RuschelCentre of Psychiatry and Research SR, Centre of Psychiatry and Research Rio de JaneiroBrazil

Rodrigo A. BressanDepartment of Psychiatry, Federal University of São PauloBrazil

Irismar Reis de OliveiraDepartment of Neurosciences and Mental Health, Federal University of Bahia Salvador, BahiaBrazil

Fábio Lopes RochaDepartment of Psychiatry, Institute of Social Security of the Civil Servants of Minas Gerais (IPSEMG), Belo Horizonte Minas GeraisBrazil

Hamilton M. GrabowskiHospital Bom Retiro Curitiba, ParanáBrazil

Ernindo Sacomani Jr.Faculty of Medicine of MaríliaBrazil

Mario R. LouzãInstitute of Psychiatry, University of São PauloBrazil

João QuevedoLaboratory of Neurosciences and National Institute for Translational Medicine (INCT-TM), University of Southern Santa Catarina Criciúma, Santa CatarinaBrazil

Hélio ElkisDepartment and Institute of Psychiatry, University of São Paulo Medical SchoolBrazil

Dirceu Zorzetto FilhoFaculty of Medicine, Federal University of Paraná CuritibaBrazil

Cintia de Azevedo-Marques PéricoFaculty of Medicine of ABC Santo André, São PauloBrazil

Fábio Lorea LawsonJanssen-Cilag Farmacêutica Ltda. São PauloBrazil

José Carlos AppolinárioInstitute of Psychiatry, Federal University of Rio de JaneiroBrazil

show all

Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date